Voyager Therapeutics Inc

VYGR

Company Profile

  • Business description

    Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

  • Contact

    75 Hayden Avenue
    LexingtonMA02421
    USA

    T: +1 857 259-5340

    E: [email protected]

    https://www.voyagertherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    141

Stocks News & Analysis

stocks

Updating our commodity price assumptions

Our view as China’s steel production drops.
stocks

Higher credit stress for big four bank

Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks

The ASX player evolving into a defensive haven

A well-timed simplification journey as boring evolves back in vogue.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,177.1016.10-0.18%
CAC 408,235.7295.32-1.14%
DAX 4024,270.87146.93-0.60%
Dow JONES (US)49,219.14223.42-0.45%
FTSE 10010,498.09110.99-1.05%
HKSE26,487.48126.410.48%
NASDAQ24,303.60100.79-0.41%
Nikkei 22559,349.17524.280.89%
NZX 50 Index12,932.3316.880.13%
S&P 5007,074.9834.16-0.48%
S&P/ASX 2008,949.4020.10-0.22%
SSE Composite Index4,085.082.950.07%

Market Movers